Aucta Pharms   Report issue

For profit Phase 1 Phase 2
Founded: North Brunswick NJ United States (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2017
NCT03363763
First Marketed Drug
2018
vigabatrin (sabril)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AUCTA | Aucta Pharmaceuticals, Inc | AUCTA PHARMS

Active Ingredients

Marketed Drugs (6)

deferasirox (exjade) (2021)

formoterol (foradil) (2022)

lacosamide (vimpat) (2023)

mexiletine (mexitil) (2022)

oxcarbazepine (trileptal) (2022)

vigabatrin (sabril) (2018)

Drugs in Phase 2 Trials (1)

sirolimus (rapamune) (1 trial)

Drugs in Phase 1 Trials (1)

entecavir (baraclude) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angiofibroma (Phase 2)

Sclerosis (Phase 2)

Tuberous Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2